Global Oncology Based Molecular Diagnostics 麻豆原创 Research Report 2023

Publication ID:

PB504240713

Publication Date:

April 26, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Medical Devices [2]

Pharma & Healthcare [3]

Description:

Molecular diagnosis of tumor refers to the molecular biological diagnosis technology with nucleic acid or protein as the core, which is an important method for early diagnosis of tumor.
Highlights
The global Oncology Based Molecular Diagnostics market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.
North American market for Oncology Based Molecular Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Oncology Based Molecular Diagnostics is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global manufacturers of Oncology Based Molecular Diagnostics include Abbott Laboratories, Bayer Healthcare, Becton Dickinson, Cepheid, Dako, Danaher Corporation, Gen Probe(Hologic), Roche Diagnostics and Siemens Healthcare, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Oncology Based Molecular Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Oncology Based Molecular Diagnostics.
The Oncology Based Molecular Diagnostics market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Oncology Based Molecular Diagnostics market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Oncology Based Molecular Diagnostics manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.
By Company
Abbott Laboratories
Bayer Healthcare
Becton Dickinson
Cepheid
Dako
Danaher Corporation
Gen Probe(Hologic)
Roche Diagnostics
Siemens Healthcare
Segment by Type
PCR
Multiplex PCR
In Situ Hybridization
Isothermal Nucleic Acid Amplification Technology (INAAT)
Segment by Application
Breast Cancer
Prostate Cancer
Colorectal Cancer
Cervical Cancer
Other
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Oncology Based Molecular Diagnostics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Oncology Based Molecular Diagnostics in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Oncology Based Molecular Diagnostics 麻豆原创 Overview
1.1 Product Overview and Scope of Oncology Based Molecular Diagnostics
1.2 Oncology Based Molecular Diagnostics Segment by Type
1.2.1 Global Oncology Based Molecular Diagnostics 麻豆原创 Value Comparison by Type (2023-2029)
1.2.2 PCR
1.2.3 Multiplex PCR
1.2.4 In Situ Hybridization
1.2.5 Isothermal Nucleic Acid Amplification Technology (INAAT)
1.3 Oncology Based Molecular Diagnostics Segment by Application
1.3.1 Global Oncology Based Molecular Diagnostics 麻豆原创 Value by Application: (2023-2029)
1.3.2 Breast Cancer
1.3.3 Prostate Cancer
1.3.4 Colorectal Cancer
1.3.5 Cervical Cancer
1.3.6 Other
1.4 Global Oncology Based Molecular Diagnostics 麻豆原创 Size Estimates and Forecasts
1.4.1 Global Oncology Based Molecular Diagnostics Revenue 2018-2029
1.4.2 Global Oncology Based Molecular Diagnostics Sales 2018-2029
1.4.3 Global Oncology Based Molecular Diagnostics 麻豆原创 Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Oncology Based Molecular Diagnostics 麻豆原创 Competition by Manufacturers
2.1 Global Oncology Based Molecular Diagnostics Sales 麻豆原创 Share by Manufacturers (2018-2023)
2.2 Global Oncology Based Molecular Diagnostics Revenue 麻豆原创 Share by Manufacturers (2018-2023)
2.3 Global Oncology Based Molecular Diagnostics Average Price by Manufacturers (2018-2023)
2.4 Global Oncology Based Molecular Diagnostics Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Oncology Based Molecular Diagnostics, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oncology Based Molecular Diagnostics, Product Type & Application
2.7 Oncology Based Molecular Diagnostics 麻豆原创 Competitive Situation and Trends
2.7.1 Oncology Based Molecular Diagnostics 麻豆原创 Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Oncology Based Molecular Diagnostics Players 麻豆原创 Share by Revenue
2.7.3 Global Oncology Based Molecular Diagnostics 麻豆原创 Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oncology Based Molecular Diagnostics Retrospective 麻豆原创 Scenario by Region
3.1 Global Oncology Based Molecular Diagnostics 麻豆原创 Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Oncology Based Molecular Diagnostics Global Oncology Based Molecular Diagnostics Sales by Region: 2018-2029
3.2.1 Global Oncology Based Molecular Diagnostics Sales by Region: 2018-2023
3.2.2 Global Oncology Based Molecular Diagnostics Sales by Region: 2024-2029
3.3 Global Oncology Based Molecular Diagnostics Global Oncology Based Molecular Diagnostics Revenue by Region: 2018-2029
3.3.1 Global Oncology Based Molecular Diagnostics Revenue by Region: 2018-2023
3.3.2 Global Oncology Based Molecular Diagnostics Revenue by Region: 2024-2029
3.4 North America Oncology Based Molecular Diagnostics 麻豆原创 Facts & Figures by Country
3.4.1 North America Oncology Based Molecular Diagnostics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Oncology Based Molecular Diagnostics Sales by Country (2018-2029)
3.4.3 North America Oncology Based Molecular Diagnostics Revenue by Country (2018-2029)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Oncology Based Molecular Diagnostics 麻豆原创 Facts & Figures by Country
3.5.1 Europe Oncology Based Molecular Diagnostics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Oncology Based Molecular Diagnostics Sales by Country (2018-2029)
3.5.3 Europe Oncology Based Molecular Diagnostics Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oncology Based Molecular Diagnostics 麻豆原创 Facts & Figures by Country
3.6.1 Asia Pacific Oncology Based Molecular Diagnostics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Oncology Based Molecular Diagnostics Sales by Country (2018-2029)
3.6.3 Asia Pacific Oncology Based Molecular Diagnostics Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Oncology Based Molecular Diagnostics 麻豆原创 Facts & Figures by Country
3.7.1 Latin America Oncology Based Molecular Diagnostics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Oncology Based Molecular Diagnostics Sales by Country (2018-2029)
3.7.3 Latin America Oncology Based Molecular Diagnostics Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oncology Based Molecular Diagnostics 麻豆原创 Facts & Figures by Country
3.8.1 Middle East and Africa Oncology Based Molecular Diagnostics 麻豆原创 Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Oncology Based Molecular Diagnostics Sales by Country (2018-2029)
3.8.3 Middle East and Africa Oncology Based Molecular Diagnostics Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Oncology Based Molecular Diagnostics Sales by Type (2018-2029)
4.1.1 Global Oncology Based Molecular Diagnostics Sales by Type (2018-2023)
4.1.2 Global Oncology Based Molecular Diagnostics Sales by Type (2024-2029)
4.1.3 Global Oncology Based Molecular Diagnostics Sales 麻豆原创 Share by Type (2018-2029)
4.2 Global Oncology Based Molecular Diagnostics Revenue by Type (2018-2029)
4.2.1 Global Oncology Based Molecular Diagnostics Revenue by Type (2018-2023)
4.2.2 Global Oncology Based Molecular Diagnostics Revenue by Type (2024-2029)
4.2.3 Global Oncology Based Molecular Diagnostics Revenue 麻豆原创 Share by Type (2018-2029)
4.3 Global Oncology Based Molecular Diagnostics Price by Type (2018-2029)
5 Segment by Application
5.1 Global Oncology Based Molecular Diagnostics Sales by Application (2018-2029)
5.1.1 Global Oncology Based Molecular Diagnostics Sales by Application (2018-2023)
5.1.2 Global Oncology Based Molecular Diagnostics Sales by Application (2024-2029)
5.1.3 Global Oncology Based Molecular Diagnostics Sales 麻豆原创 Share by Application (2018-2029)
5.2 Global Oncology Based Molecular Diagnostics Revenue by Application (2018-2029)
5.2.1 Global Oncology Based Molecular Diagnostics Revenue by Application (2018-2023)
5.2.2 Global Oncology Based Molecular Diagnostics Revenue by Application (2024-2029)
5.2.3 Global Oncology Based Molecular Diagnostics Revenue 麻豆原创 Share by Application (2018-2029)
5.3 Global Oncology Based Molecular Diagnostics Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Abbott Laboratories
6.1.1 Abbott Laboratories Corporation Information
6.1.2 Abbott Laboratories Description and Business Overview
6.1.3 Abbott Laboratories Oncology Based Molecular Diagnostics Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Abbott Laboratories Oncology Based Molecular Diagnostics Product Portfolio
6.1.5 Abbott Laboratories Recent Developments/Updates
6.2 Bayer Healthcare
6.2.1 Bayer Healthcare Corporation Information
6.2.2 Bayer Healthcare Description and Business Overview
6.2.3 Bayer Healthcare Oncology Based Molecular Diagnostics Sales, Revenue and Gross Margin (2018-2023)
6.2.4 Bayer Healthcare Oncology Based Molecular Diagnostics Product Portfolio
6.2.5 Bayer Healthcare Recent Developments/Updates
6.3 Becton Dickinson
6.3.1 Becton Dickinson Corporation Information
6.3.2 Becton Dickinson Description and Business Overview
6.3.3 Becton Dickinson Oncology Based Molecular Diagnostics Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Becton Dickinson Oncology Based Molecular Diagnostics Product Portfolio
6.3.5 Becton Dickinson Recent Developments/Updates
6.4 Cepheid
6.4.1 Cepheid Corporation Information
6.4.2 Cepheid Description and Business Overview
6.4.3 Cepheid Oncology Based Molecular Diagnostics Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Cepheid Oncology Based Molecular Diagnostics Product Portfolio
6.4.5 Cepheid Recent Developments/Updates
6.5 Dako
6.5.1 Dako Corporation Information
6.5.2 Dako Description and Business Overview
6.5.3 Dako Oncology Based Molecular Diagnostics Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Dako Oncology Based Molecular Diagnostics Product Portfolio
6.5.5 Dako Recent Developments/Updates
6.6 Danaher Corporation
6.6.1 Danaher Corporation Corporation Information
6.6.2 Danaher Corporation Description and Business Overview
6.6.3 Danaher Corporation Oncology Based Molecular Diagnostics Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Danaher Corporation Oncology Based Molecular Diagnostics Product Portfolio
6.6.5 Danaher Corporation Recent Developments/Updates
6.7 Gen Probe(Hologic)
6.6.1 Gen Probe(Hologic) Corporation Information
6.6.2 Gen Probe(Hologic) Description and Business Overview
6.6.3 Gen Probe(Hologic) Oncology Based Molecular Diagnostics Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Gen Probe(Hologic) Oncology Based Molecular Diagnostics Product Portfolio
6.7.5 Gen Probe(Hologic) Recent Developments/Updates
6.8 Roche Diagnostics
6.8.1 Roche Diagnostics Corporation Information
6.8.2 Roche Diagnostics Description and Business Overview
6.8.3 Roche Diagnostics Oncology Based Molecular Diagnostics Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Roche Diagnostics Oncology Based Molecular Diagnostics Product Portfolio
6.8.5 Roche Diagnostics Recent Developments/Updates
6.9 Siemens Healthcare
6.9.1 Siemens Healthcare Corporation Information
6.9.2 Siemens Healthcare Description and Business Overview
6.9.3 Siemens Healthcare Oncology Based Molecular Diagnostics Sales, Revenue and Gross Margin (2018-2023)
6.9.4 Siemens Healthcare Oncology Based Molecular Diagnostics Product Portfolio
6.9.5 Siemens Healthcare Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oncology Based Molecular Diagnostics Industry Chain Analysis
7.2 Oncology Based Molecular Diagnostics Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oncology Based Molecular Diagnostics Production Mode & Process
7.4 Oncology Based Molecular Diagnostics Sales and 麻豆原创ing
7.4.1 Oncology Based Molecular Diagnostics Sales Channels
7.4.2 Oncology Based Molecular Diagnostics Distributors
7.5 Oncology Based Molecular Diagnostics Customers
8 Oncology Based Molecular Diagnostics 麻豆原创 Dynamics
8.1 Oncology Based Molecular Diagnostics Industry Trends
8.2 Oncology Based Molecular Diagnostics 麻豆原创 Drivers
8.3 Oncology Based Molecular Diagnostics 麻豆原创 Challenges
8.4 Oncology Based Molecular Diagnostics 麻豆原创 Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 麻豆原创 Size Estimation
10.1.3 麻豆原创 Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer

Companies Mentioned:

Abbott Laboratories
Bayer Healthcare
Becton Dickinson
Cepheid
Dako
Danaher Corporation
Gen Probe(Hologic)
Roche Diagnostics
Siemens Healthcare

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.